XWELL

Overview

Publicly traded wellness and biosecurity company (Nasdaq: XWEL), parent of XpresTest in 2026; announced approximately $31.3 million American Ventures placement before XpresTest federal awards.

Its financing, subsidiary contracts and proposed divestiture form a documented investment-to-award chronology.

Company history

XWELL developed airport spa and wellness services and, through XpresTest, traveler disease screening. It previously participated in federally funded COVID-19 surveillance and testing.

Financing and federal awards

In February 2026, XWELL announced a securities placement of approximately $31.3 million with an American Ventures series. ProPublica reported subsequent XpresTest awards of about $18.8 million for CDC Ebola entry screening and $20 million for State Department-supported outbreak response in the Democratic Republic of Congo. These are award values, not proof of total payment.

Proposed sale

XWELL's July 2026 agreement proposed selling XpresTest and XpresSpa for a $13 million base price, subject to adjustments and closing conditions. Shareholders approved the sale on October 28. Approval does not demonstrate the transaction had closed as of November 9.

Contract-related commissions

XWELL's October proxy described post-sale profit-based commission arrangements relating to the CDC contract for named company officials, including its chairman and CEO. These are disclosed contingent arrangements, not independently established misconduct.

Limits and responses

ProPublica reported experience with domestic airport screening but not prior Ebola work abroad. XWELL's CEO described international deployment risks; the State Department described its award process as competitive. No verified record cited here establishes improper procurement influence.

Documented relationships

• American Ventures

  A series invested approximately $31.3 million through a preferred-stock and warrant private placement announced February 24 · 2026 · Evidence (documented)

• XpresTest

  Parent/subsidiary relationship at the time of 2026 federal awards; proposed sale remained subject to conditions · 2026 · Evidence (documented)

A documented investment, family relationship or federal award does not establish undue influence or illegal conduct. Reported award ceilings are not the same as money paid.

Focused relationship map

View the full interactive relationship map

Related entries

• XpresTest
• American Ventures
• Dominari Holdings
• Centers for Disease Control and Prevention
• U.S. Department of State

Sources

1. XWELL February 2026 securities placement
2. XWELL October 2026 proxy statement — subsidiary sale, CDC contract and commissions
3. XWELL October 28 shareholder vote filing
4. ProPublica November 9 investigation

Source status: SEC filings and organizational records establish the transactions and affiliations described; ProPublica independently reports the federal awards and attributed responses. Where original award files have not been obtained, claims remain attributed.